1250% Dividend: Midcap Pharma Stock Sets Record Date, Scrip Rallies 12.22%, Hits 52-Week-High

The shares of Ajanta Pharma rallied 12.22% to hit a new 52-week-high Rs 1,735.10 apiece after the company's consolidated net profit jumped 19% to Rs 208.12 Crore. With a 19% rise in revenue and PAT, Ajanta Pharma reported Q1 revenue of Rs. 1,021 crore, EBITDA of Rs. 271 crore, and PAT of Rs. 208 crore.

For the financial year 2023-2024, the Board of Directors of the company announces a first interim dividend of Rs. 315 crore, which includes a special payment of Rs. 25 per share to celebrate its 50th anniversary.

1st Interim Dividend & Record Date

"1st interim dividend of Rs. 315 cr. for the year FY 2024. It translates into Rs. 25 per share (1250%) on face value of Rs. 2/- per share. This total dividend of Rs. 25 per share includes a regular dividend of Rs. l0 per share, and an additional Rs. 15 per share, distributed as a special dividend on the commemoration of 50 years of momentous journey of the Company," the Board of Directors of the company has said.

It added, "Fixed Friday, 4th August 2023 as the Record date for payment of interim dividend and special dividend. Dividend will be paid on or after I1th August 2023."

Stock Movement

The shares of Ajanta Pharma hit a new 52-week-high at Rs 1735.10 apiece in early trade, currently trading at Rs 1685.05 apiece, up 8.98%, from its previous close. The stock's 52-week-low is Rs 1115.15 apiece.

The stock gained 18.14% in 1 week, while in 1 and 3 months, it gained 12.78% and 26.64%, respectively. It gained 31.04% in 1 year. It gained 73.69% in 3 years and 128.97% in 5 years, respectively.

About - Ajanta Pharma Ltd.

Ajanta Pharma is a specialty pharmaceutical company providing quality medicines across 30+ countries in the world. It is a midcap pharma company with a market cap of Rs 21,229.38 Crore.

Disclaimer - The stock just highlights the dividend and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither the author nor Greynium Information Technologies should be held liable for any losses. Please consult a professional advisor.